Tralokinumab  (Synonyms: 曲罗芦单抗; CAT354)

Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis^[1][2].

Human IgG4 lambda

Human IgG4 (S228P) lambda1, Isotype Control

Tralokinumab (3 mg/kg; 腹腔注射; 每隔一天一次; 从第 35 天到第 63 天) 在人源化肺纤维化 SCID 小鼠模型中，可抑制肺纤维化并减少肺上皮细胞凋亡^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

3596  [NCBI]

P35225

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.14 kDa

1044515-88-9

液体

Colorless to light yellow

曲罗芦单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 lambda

• 
  Immobilized Human IL-13 Protein (His Tag) can bind Tralokinumab. The EC₅₀ for this effect is 70.22 ng/mL.

• [1]. A Wollenberg, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021 Mar;184(3):437-449.  [Content Brief]

  [2]. Murray LA, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. 2014 May;50(5):985-94.  [Content Brief]